在mTOR/HIF-1α途径中介的葡萄糖重编程和巨分极通过Sini脱加人参在ALF中的
Junli Zhang1, Liyuan Hao2, Shenghao Li2
1Chengdu University of Traditional Chinese Medicine, No. 37 Shi-er-qiao Road, Chengdu 610075, Sichuan Province, PR China; Department of Infectious Diseases, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Qinghuai District, Nanjing, Jiangsu 210029, PR China.
概括
锡尼加人参 (SNRS) 显示,通过通过mTOR/HIF-1α通路重新编程巨细胞的葡萄糖代谢和两极分化,改善生存率和减少肝损伤,有望治疗急性肝衰竭 (ALF).
科学领域:
- 综合医学是一个整体的医学.
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 代谢途径 代谢途径
背景情况:
- 急性肝衰竭 (ALF) 是一个重大的临床挑战,死亡率高,长期结果不佳.
- 目前对ALF的治疗策略在改善患者的生存和康复方面存在局限性.
研究的目的:
- 调查ALF中Sini Decoction加人参 (SNRS) 的治疗点和分子途径.
- 通过重新编程葡萄糖代谢,阐明SNRS在调节巨细胞极化中的机制.
- 在ALF模型中验证SNRS疗效,并确定体外研究的最佳度.
主要方法:
- 对GEO数据集的生物信息学分析,以识别ALF中的差异表达基因 (DEG).
- 网络药理学预测SNRS的治疗点和途径.
- 在体内验证,使用脂多糖/D-银胺 (LPS/D-GalN) 诱导的ALF模型.
- 在体外研究评估巨细胞极化,糖解和关键信号通路 (mTOR/HIF-1α).
主要成果:
- 鉴定了五个关键的糖解调节基因 (HK2,CDK1,SOD1,VEGFA,GOT1),与HIF-1信号通路有关.
- 在ALF模型中,SNRS治疗显著改善了生存率,降低了肝酶 (AST,ALT),并减轻了肝脏组织病理.
- 在实验室中,SNRS调节了巨细胞极化,减少了M1标记物 (CD86) 和增加了M2标记物 (CD163),同时抑制了炎症反应和乳酸盐产生.
结论:
- 在ALF中,SNRS有效调节巨细胞极化和葡萄糖代谢重编程.
- mTOR/HIF-1α通路是SNRS在ALF治疗效果的关键调解者.
- 在治疗急性肝衰竭方面,SNRS显示出显著的治疗潜力.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


